Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
28.47
+0.85 (3.08%)
At close: Apr 8, 2026, 4:00 PM EDT
28.47
0.00 (0.00%)
After-hours: Apr 8, 2026, 4:00 PM EDT
HRMY Employees
Harmony Biosciences Holdings had 293 employees as of December 31, 2025. The number of employees increased by 25 or 9.33% compared to the previous year.
Employees
293
Change (1Y)
25
Growth (1Y)
9.33%
Revenue / Employee
$2,964,003
Profits / Employee
$541,594
Market Cap
1.65B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 293 | 25 | 9.33% |
| Dec 31, 2024 | 268 | 22 | 8.94% |
| Dec 31, 2023 | 246 | 46 | 23.00% |
| Dec 31, 2022 | 200 | 20 | 11.11% |
| Dec 31, 2021 | 180 | 30 | 20.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| AnaptysBio | 104 |
| Nanobiotix | 103 |
| Rapport Therapeutics | 84 |
| MBX Biosciences | 63 |
HRMY News
- 6 days ago - Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board - Business Wire
- 8 days ago - Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference - Business Wire
- 5 weeks ago - Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion - Business Wire
- 7 weeks ago - Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy - Business Wire
- 2 months ago - Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Business Wire
- 3 months ago - Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation - Business Wire
- 3 months ago - Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire